Targeting LHON and Retinitis Pigmentosa With Gene Therapy

Video

Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed the company’s work in ophthalmic diseases.

“We have 2 technology platforms. The first 1 is a technology platform to overcome mitochondrial mutation and we are developing it in Leber hereditary optic neuropathy. And the second technology platform is also important, we are developing optogenetic therapy; right now we are in early phase in retinitis pigmentosa and the beauty of this program is that it's independent to causal mutation.”

GenSight Biologics is aiming to use gene therapy methods to combat ophthalmic diseases. The company currently has programs in Leber hereditary optic neuropathy (LHON) and retinitis pigmentosa (RP) and is also setting its sights on dry age-related macular degeneration (AMD).

Recent data from GenSight’s phase 3 REFLECT trial (NCT03293524) showed that patients treated with lenadogene nolparvovec (Lumevoq; GS010) had statistically significant improvements in visual acuity from baseline in the first affected eye with both unilateral (+0.15 LogMAR score [+8 ETDRS letters]; P <.05) and bilateral (+0.23 LogMAR score [+12 ETDRS letters]; P = .001) injections. 

GeneTherapyLive spoke with GenSight’s chief medical officer, Magali Taiel, MD, about the company’s background and technology platforms. She also discussed the need for gene therapies in ophthalmic diseases and partnerships the company has with academic institutions.

REFERENCE
GenSight Biologics reports topline results from REFLECT phase III clinical trial, confirming Lumevoq efficacy including better efficacy with bilateral treatment. News release. GenSight Biologics. June 30, 2021. https://www.gensight-biologics.com/2021/06/30/gensight-biologics-reports-topline-results-from-reflect-phase-iii-clinical-trial-confirming-lumevoq-efficacy-including-better-efficacy-with-bilateral-treatment/
Related Videos
Xandra Breakefield, PhD, on Trying New Approaches to AAV Therapy for Glioblastoma
Nathan Yozwiak, PhD, on Researching AAV Gene Therapy Delivery to the Brain
Salvador Rico, MD, PhD, on Informing Clinical Trials With Natural History Studies in Dravet
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
© 2024 MJH Life Sciences

All rights reserved.